Extended dosage regimens for anti-CD20 antibodies in the treatment of multiple sclerosis

DE112024003809T5Undetermined Publication Date: 2026-08-06NOVARTIS AG
View PDF 13 Cites 0 Cited by

Patent Information

Authority / Receiving Office
DE · DE
Patent Type
Applications
Current Assignee / Owner
NOVARTIS AG
Filing Date
2024-10-09
Publication Date
2026-08-06
Patent Text Reader

Abstract

The disclosure relates to treatment regimens for multiple sclerosis (MS). These regimens include the subcutaneous administration of anti-CD20 antibodies, which provide efficacy and safety even with extended subcutaneous dosing intervals.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Binding domain-immunoglobulin fusion proteins

    US20030118592A1

  • Eye-Tracking System and Method Therefor

    US20170276934A1

  • Apparatus and method for hybrid eye tracking

    US20180342066A1

  • Anti-CD20 antibodies and fusion proteins thereof and methods of use

    WO2003068821A2

  • Human monoclonal antibodies against CD20

    WO2004035607A2